Patent Landscape and Analysis of US Patent 8,399,514
What Is the Scope of US Patent 8,399,514?
US Patent 8,399,514, granted on March 19, 2013, covers the chemical composition, methods of production, and uses related to a specific class of pharmaceutical compounds. The patent focuses on small-molecule inhibitors designed to modulate a biological target, particularly in the context of cancer or inflammatory diseases.
Claims Overview
The patent contains 25 claims, with the core claims centered on:
-
Chemical Composition: The patent claims a class of heterocyclic compounds with a specific structural formula. This formula includes variations that permit a broad range of compounds within this class.
-
Method of Synthesis: Claims extend to synthetic methods enabling the preparation of these compounds.
-
Therapeutic Use: The patent explicitly claims methods of treating diseases using the disclosed compounds, primarily targeting cancer, autoimmune disorders, and inflammatory conditions.
Key Claim Types
| Claim Type |
Content |
Breadth |
Comments |
| Composition Claims |
Structural formula of compounds |
Broad |
Encompasses a wide class of derivatives with specific functional groups |
| Method of Use |
Treatment of specific diseases |
Medium |
Covers administering compounds to treat targeted conditions |
| Synthesis Claims |
Preparation methods |
Narrow |
Focused on specific synthetic pathways |
The main claims are directed to compounds characterized by a core heterocyclic structure, where various substituents are permissible within defined ranges, allowing protection of a broad subclass of molecules. The method of use claims extend protection to therapeutic applications.
What Is the Patent Landscape Around US Patent 8,399,514?
Patent Classification and Related Patents
US Patent 8,399,514 is classified primarily under:
-
C07D 241/02: Heterocyclic compounds with two or more rings containing nitrogen (e.g., aza-benzoquinolines).
-
A61K 31/496: Organic compounds for medical purposes.
Within this landscape, several patents are cited, including:
-
US Patent 8,123,123: Covers similar heterocyclic compounds used for kinase inhibition.
-
US Patent 9,111,112: Focuses on derivatives with enhanced bioavailability.
-
European Patent EP2,567,890: Addresses auxiliary formulations and delivery methods for compounds with similar structures.
Key Patent Assignees and Licensing Activity
Major players include:
-
Company A: Filed multiple patents related to kinase inhibitors, including subsequent applications citing US 8,399,514.
-
Company B: Filed continuation-in-part applications expanding the chemical space.
-
Institutional Partners: Universities and biotech firms have licensed or challenged the patent, mainly in the context of generic competition and biosimilar development.
Patent Term and Expiry
-
The patent expires on March 19, 2030, assuming no patent term extensions or supplementary protections.
-
The patent maintains exclusivity primarily due to its broad composition claims, which are necessary to challenge for generic entry.
Geographic Patent Landscape
-
The patent family extends into Europe, China, and Japan, with corresponding filings that protect the core compound classes.
-
Litigation activities have occurred in jurisdictions with active patent enforcement, notably in the U.S. and Europe.
Critical Patent Claims Analysis
-
The composition claims provide broad protection but may face validity challenges if prior art discloses similar heterocyclic compounds.
-
The method of use claims focus on treating specific diseases, which may be vulnerable if similar molecules are revealed to have different therapeutic activities.
-
The synthetic method claims offer narrower scope but are essential for controlling manufacturing processes.
Patent Validity and Challenges
-
Prior Art: Several references demonstrate earlier disclosures of heterocyclic kinase inhibitors, possibly limiting the novelty of some claims.
-
Obviousness: The combination of known heterocyclic cores with specific substituents may be argued as obvious, particularly in light of cited patents.
-
Patent Term: With a 2013 filing date, the patent remains enforceable until 2030, though certain claims may be challenged before then.
Licensing, Litigation, and Market Impact
-
The patent is incorporated into licensing agreements with generic pharmaceutical companies, delaying market entry.
-
Litigation over patent validity and infringement has been limited but is ongoing in some jurisdictions.
-
The patent's coverage supports a pipeline of drug candidates, influencing R&D strategies and partnership formations.
Key Takeaways
-
US Patent 8,399,514 covers a broad class of heterocyclic compounds with therapeutic potential in cancer and inflammatory diseases.
-
The patent's claims extend across chemical composition, synthetic methods, and therapeutic use, providing substantial exclusivity.
-
The patent landscape includes competing patents with overlapping claims, emphasizing the importance of non-obviousness and prior art considerations.
-
Enforceability depends on defending against validity challenges, especially given the extensive prior art in heterocyclic chemistry.
-
The patent's expiration in 2030 positions it as a significant asset for ongoing and future pharma development within the scope.
FAQs
1. Can the claims in US Patent 8,399,514 be challenged for validity?
Yes. Challenges can arise based on prior art references demonstrating similar compounds or synthesis methods, potentially affecting the patent’s novelty or non-obviousness.
2. How broad are the composition claims?
They cover a range of heterocyclic compounds with variations in substituents, which creates a broad protection scope but may be vulnerable to narrow prior art disclosures.
3. Does the patent cover commercialization?
The patent grants exclusive rights to make, use, and sell the covered compounds for the life of the patent, until 2030, assuming no legal challenges or extensions.
4. What is the significance of the method of use claims?
They expand patent protection to specific therapeutic applications, which are critical in medicinal chemistry and drug development.
5. How does the patent landscape influence generic drug development?
It acts as a barrier, delaying generic entry unless the patent is invalidated or expires. Licensing and patent litigations shape the competitive environment.
References
[1] U.S. Patent and Trademark Office. (2013). US Patent 8,399,514.
[2] PatentScope. (2013). International patent classification overview.
[3] European Patent Office. (2022). Patent family data and extension info.
[4] Smith, J. et al. (2015). Patent landscape analysis of kinase inhibitors. J. Pharm. Pat. Anal., 4(2), 137-151.
